Effect of atorvastatin on ulcer

Phase 3

Conditions: Post-operative wounds.

Registration Number: IRCT20190810044500N3

Lead Sponsor: Yazd University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 60

Inclusion Criteria

Candidates for laparotomy surgery over 18 years old
Sufficient literacy to fill out a consent form, understand the study, use the drug, report pain and possible side effects

Exclusion Criteria

Pregnant and lactating women
Patients with any peripheral or central neuropathic pain
Patients with a history of psychosis
Patients with a history of inflammatory disease who cannot discontinue NSAIDs or analgesics.
Patients with oral atorvastatin

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Redness. Timepoint: Before the start of the intervention - The first day -The seventh day -The fourteenth day. Method of measurement: Redness, Oedema, Ecchymosis, Discharge, Approximation (REEDA) scale.;Oedema. Timepoint: Before the start of the intervention - The first day -The seventh day -The fourteenth day. Method of measurement: REEDA Scale.;Ecchymosis. Timepoint: Before the start of the intervention - The first day -The seventh day -The fourteenth day. Method of measurement: REEDA Scale.;Wound Secretion. Timepoint: Before the start of the intervention - The first day -The seventh day -The fourteenth day. Method of measurement: REEDA Scale.;Approximation. Timepoint: Before the start of the intervention - The first day -The seventh day -The fourteenth day. Method of measurement: REEDA Scale.

Secondary Outcome Measures

Name	Time	Method
Quality of Life. Timepoint: On days 1, 7 and 14. Method of measurement: According to the Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30 (version 3).;Visual analog scale (VAS). Timepoint: baseline, days 1, 2, , and 14. Method of measurement: The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').;Unexpected adverse effects. Timepoint: At the end of the study. Method of measurement: Examining and asking the patient.